In collaboration with the University Hospital in Southampton, UK and the School of Medicine of the Federal University of Minas Gerais, Brazil, we have developed a multiplexed lateral flow device for diagnosis of Visceral Leishmaniasis.

During pre-clinical studies, we demonstrated that our proprietary device performs better than the current commercial alternative both in terms of sensitivity and specificity.

In collaboration with the University Hospital in Southampton, UK,  we have developed a multiplexed lateral flow device for diagnosis of Tuberculosis.

The device is based on diagnosis of several relevant biomarkers and a novel proprietary biomarker identified in UHS.